Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H. Wilson, Rod Humerickhouse, Owen A. O’Connor et al.|The Lancet Oncology|2010Cited by 852
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S. Davids, John F. Seymour, Jeffrey A. Jones et al.|Clinical Cancer Research|2018Cited by 161
Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)Matthew S. Davids, Andrew W. Roberts, John M. Pagel et al.|Blood|2013Cited by 69
The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) PatientsMatthew S. Davids, Andrew W. Roberts, John F. Seymour et al.|Blood|2013Cited by 53
The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I StudyMatthew S. Davids, John F. Seymour, Andrew W. Roberts et al.|Blood|2012Cited by 40